Edelmann, Jennifer, Dokal, Arran D., Vilventhraraja, Emma, Holzmann, Karlheinz, Britton, David, Klymenko, Tetyana, Döhner, Hartmut, Cragg, Mark, Braun, Andrejs, Cutillas, Pedro and Gribben, John G.
(2021)
Rituximab and obinutuzumab differentially hijack the B-cell receptor and NOTCH1 signaling pathways.
iScience, 24 (2), [102089].
(doi:10.1016/j.isci.2021.102089).
More information
Accepted/In Press date: 18 January 2021
e-pub ahead of print date: 22 January 2021
Published date: 19 February 2021
Additional Information:
Funding Information:
The study was supported by the German Research Foundation ( ED 256/1-1 ), the Barts Charity Fund, NIH ( NCI PO1 CA81534 ), the Barry Reed Cancer Research Fund, and the Clinician Scientist Program of the Medical Faculty, Ulm University .
Funding Information:
We thank Sameena Iqubal and Janet Matthews from Barts Cancer Institute for their help with the acquisition of primary CLL samples, Ryan Smith from Barts Cancer Institute for his help with the analysis of LC-MS/MS raw data, Graham Packham and Stephen Beers from Southampton University for helpful discussions, and Doriana di Bella from Barts Cancer Institute for her assistance with experiments. The study was supported by the German Research Foundation (ED 256/1-1), the Barts Charity Fund, NIH (NCI PO1 CA81534), the Barry Reed Cancer Research Fund, and the Clinician Scientist Program of the Medical Faculty, Ulm University. All authors contributed extensively to the work presented in this paper. J.E. designed research; performed, analyzed, and interpreted experiments; and wrote the paper. A.D.D. designed and performed the LC-MS/MS experiment, analyzed the raw data, and contributed to interpretation of the LC-MS/MS experiment. E.V. designed and performed the LC-MS/MS experiment. K.H. analyzed experimental data. M.C. and A.B. contributed to research design and data interpretation. H.D. contributed to data interpretation. P.C. contributed to design, analysis, and interpretation of the LC-MS/MS experiment. J.G.G. contributed to research design and interpretation. All authors contributed to write the paper. A.D.D. is Senior Scientist at Kinomica Ltd. E.V. is employed by The Janssen Pharmaceutical Companies of Johnson & Johnson. D.B. is Academic Funder and CSO at Kinomica Ltd. M.C. acts as a consultant for a number of biotech companies, being retained as a consultant for BioInvent and has received research funding from BioInvent, GSK, UCB, iTeos, and Roche. P.C. is Academic Funder and Director at Kinomica Ltd. Disclosures J.G.G.: Janssen: Advisory Board, Honoraria, Research funding; Acerta: Advisory Board, Honoraria, Research funding; Celgene: Advisory Board, Honoraria, Research funding; Kite: Advisory Board, Honoraria; AbbVie: Advisory Board, Honoraria; Novartis: Advisory Board; TG Therapeutics: Advisory Board. Disclosures H.D.: Abbvie: Consultancy, Honoraria; Agios: Consultancy, Honoraria, Research funding; Amgen: Consultancy, Honoraria, Research Funding; AROG: Research funding; Astellas: Consultancy, Honoraria, Research funding; Astex: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research funding; Janssen: Consultancy, Honoraria; Jazz: Consultancy, Honoraria, Research Funding; Helsinn: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research funding; Oxford Biomedicals: Consultancy, Honoraria; Pfizer: Research funding; Roche: Consultancy, Honoraria; Sunesis: Research funding; AstraZeneca: Consultancy, Honoraria; GEMoaB: Consultancy, Honoraria. The remaining authors declare no competing interests.
Funding Information:
M.C. acts as a consultant for a number of biotech companies, being retained as a consultant for BioInvent and has received research funding from BioInvent , GSK , UCB , iTeos , and Roche .
Funding Information:
Disclosures H.D.: Abbvie: Consultancy, Honoraria; Agios : Consultancy, Honoraria, Research funding; Amgen : Consultancy, Honoraria, Research Funding; AROG : Research funding; Astellas : Consultancy, Honoraria, Research funding; Astex: Consultancy, Honoraria; Bristol Myers Squibb : Consultancy, Honoraria, Research Funding; Celgene : Consultancy, Honoraria, Research funding; Janssen : Consultancy, Honoraria; Jazz: Consultancy, Honoraria, Research Funding; Helsinn : Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research funding; Oxford Biomedicals : Consultancy, Honoraria; Pfizer: Research funding; Roche : Consultancy, Honoraria; Sunesis: Research funding; AstraZeneca: Consultancy, Honoraria; GEMoaB: Consultancy, Honoraria.
Publisher Copyright:
© 2021 The Authors
Keywords:
cancer, immunology, systems biology: proteomics
Identifiers
Local EPrints ID: 446918
URI: http://eprints.soton.ac.uk/id/eprint/446918
PURE UUID: 6708cde8-5186-4ea9-99b8-22fa8cae4548
Catalogue record
Date deposited: 26 Feb 2021 17:31
Last modified: 17 Mar 2024 02:46
Export record
Altmetrics
